Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
$11.20
+8.9%
$9.51
$6.71
$17.00
$490.53MN/A248,173 shs85,577 shs
Precigen, Inc. stock logo
PGEN
Precigen
$1.41
+2.9%
$1.44
$0.65
$2.17
$416.20M1.821.33 million shs1.59 million shs
PureTech Health plc stock logo
PRTC
PureTech Health
$17.42
-4.3%
$17.21
$13.30
$32.98
$418.29M1.144,687 shs4,294 shs
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$3.31
+3.4%
$3.42
$1.52
$16.94
$86.33M2.31799,364 shs74,508 shs
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
+8.95%+10.78%+36.42%-4.27%+1,119,999,900.00%
Precigen, Inc. stock logo
PGEN
Precigen
+2.92%0.00%-6.00%-22.10%+3.68%
PureTech Health plc stock logo
PRTC
PureTech Health
-4.31%-0.03%+0.90%-6.27%-40.46%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
+3.44%+3.44%-33.80%-14.25%-2.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
3.5634 of 5 stars
3.50.00.04.72.31.70.6
PureTech Health plc stock logo
PRTC
PureTech Health
2.0513 of 5 stars
3.84.00.00.02.30.00.0
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
2.1241 of 5 stars
3.53.00.00.01.70.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
3.40
Buy$25.67129.17% Upside
Precigen, Inc. stock logo
PGEN
Precigen
3.00
Buy$7.00396.45% Upside
PureTech Health plc stock logo
PRTC
PureTech Health
3.50
Strong Buy$45.00158.40% Upside
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
3.00
Buy$12.00262.54% Upside

Current Analyst Ratings Breakdown

Latest SNTI, PGEN, MAZE, and PRTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Precigen, Inc. stock logo
PGEN
Precigen
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/2/2025
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
4/2/2025
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
3/20/2025
Precigen, Inc. stock logo
PGEN
Precigen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
$167.50M2.93N/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
$4.20M99.07N/AN/A$0.48 per share2.94
PureTech Health plc stock logo
PRTC
PureTech Health
$4.32M96.94N/AN/A$16.94 per share1.03
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$2.56M33.72N/AN/A$15.02 per share0.22
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
-$95.90M-$0.56N/AN/AN/A-3,521.68%-123.06%-87.33%8/13/2025 (Estimated)
PureTech Health plc stock logo
PRTC
PureTech Health
-$65.70MN/A0.00N/AN/AN/AN/AN/AN/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-$71.06M-$10.84N/AN/AN/AN/A-154.84%-77.42%8/12/2025 (Estimated)

Latest SNTI, PGEN, MAZE, and PRTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
-$0.76-$1.15-$0.39-$1.15N/AN/A
5/14/2025Q1 2025
Precigen, Inc. stock logo
PGEN
Precigen
-$0.08-$0.07+$0.01-$0.18$0.50 million$1.34 million
5/6/2025Q1 2025
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-$0.56-$1.41-$0.85-$1.41$1.30 million$1.30 million
3/31/2025N/A
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
-$7.60-$18.32-$10.72-$18.32N/AN/A
3/20/2025Q4 2024
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-$3.13-$0.67+$2.46-$0.67$2.80 million$5.86 million
3/19/2025Q4 2024
Precigen, Inc. stock logo
PGEN
Precigen
-$0.06-$0.04+$0.02-$0.06$1.30 million$1.19 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
N/AN/AN/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
N/AN/AN/AN/AN/A
PureTech Health plc stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
N/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
N/A
1.63
1.63
PureTech Health plc stock logo
PRTC
PureTech Health
N/A
3.68
N/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
N/A
1.92
1.92

Institutional Ownership

CompanyInstitutional Ownership
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
N/A
Precigen, Inc. stock logo
PGEN
Precigen
33.51%
PureTech Health plc stock logo
PRTC
PureTech Health
0.04%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
25.73%

Insider Ownership

CompanyInsider Ownership
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
N/A
Precigen, Inc. stock logo
PGEN
Precigen
44.90%
PureTech Health plc stock logo
PRTC
PureTech Health
5.30%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
3.12%
CompanyEmployeesShares OutstandingFree FloatOptionable
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
12143.80 millionN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
190295.18 million161.37 millionOptionable
PureTech Health plc stock logo
PRTC
PureTech Health
10024.02 million22.67 millionNot Optionable
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
426.08 million4.30 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Maze Therapeutics stock logo

Maze Therapeutics NASDAQ:MAZE

$11.20 +0.92 (+8.95%)
As of 05/27/2025 04:00 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Precigen stock logo

Precigen NASDAQ:PGEN

$1.41 +0.04 (+2.92%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.42 +0.02 (+1.06%)
As of 05/27/2025 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$17.42 -0.79 (-4.31%)
Closing price 05/27/2025 03:58 PM Eastern
Extended Trading
$18.31 +0.90 (+5.14%)
As of 05:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Senti Biosciences stock logo

Senti Biosciences NASDAQ:SNTI

$3.31 +0.11 (+3.44%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$3.22 -0.09 (-2.72%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.